Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug ATTO-1091 put to the test for safety in ulcerative colitis

NCT ID NCT07819799

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are running a phase 1 trial to find out how safe and tolerable ATTO-1091 is in healthy adults and in people with ulcerative colitis. The study also measures how long the drug stays in the body. About 96 participants will receive either ATTO-1091 or a placebo, visit the clinic for checkups, and keep a diary of symptoms. The main goal is to track medical problems and laboratory changes, not to see if the drug works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ATTO-1091, an experimental drug given as an injection or infusion
What this could lead to
If ATTO-1091 proves safe and stays in the body as intended, it could become a new treatment option for ulcerative colitis.
What could go wrong
This is a first-in-human phase 1 trial with about 96 participants, so most drugs at this stage fail or cause unexpected side effects. The trial does not test whether the drug actually treats ulcerative colitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 96 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Parts 1\&2 (Healthy Volunteers) Key Inclusion Criteria: * Any sex or gender who is 18 to 60 years old, inclusive, at Screening. * Body weight of 45 to 125 kg, inclusive, and body mass index (BMI) between 18.5 and 35 kg/m2. * Considered in good general health based on medical history, physical exam, 12-lead ECG, screening clinical laboratory findings, and vital signs. * Meets contraception requirements * Negative pregnancy test for participants of childbearing potential. Part 3 (Participants with Ulcerative Colitis) Key Inclusion Criteria: * Any sex or gender who is 18 to 80 years old * Body weight of 45 to 125 kg and BMI between 17.0 and 40.0 kg/m2 * UC diagnosis confirmed by endoscopy and histology ≥3 months prior to Screening * Moderately to severely active UC as defined by Modified Mayo Clinic Score (stool frequency, rectal bleeding, endoscopy) 5 to 9 inclusive, with Mayo endoscopic subscore ≥2 as confirmed by the central reader during Screening * Rectal bleeding subscore ≥1 and stool frequency subscore ≥1 at Screening. * Naïve to treatment with advanced therapies or has had an inadequate response, loss of response, or intolerance to no more than 3 drugs in 2 classes of the following: * Tumor necrosis factor (TNF-α) antagonists * Interleukin IL-12/IL-23 antagonists * Integrin inhibitors * JAK antagonists * S1P receptor agonists * Novel class with biologic-like activity (e.g. TL1A antagonists) * Meets washout criteria for prior UC therapies as specified in the protocol. * Negative pregnancy test for participants of childbearing potential Parts 1\&2 (Healthy Volunteers) Key Exclusion Criteria * Any clinically significant underlying illness * History of malignancy within 5 years of Screening * History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of uncontrolled asthma requiring systemic corticosteroids or hospitalization for asthma within 6 months prior to Day 1 * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) or is positive for HIV * Active or latent tuberculosis infection * Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent to approximately 40 mg nicotine) per day * History of drug or alcohol abuse * Laboratory values outside of the normal range considered clinically significant by the investigator Part 3 (Participants with Ulcerative Colitis) Key Exclusion Criteria: * Any clinically significant underlying illness * History of malignancy within 5 years of Screening * History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of uncontrolled asthma requiring systemic corticosteroids or hospitalization for asthma within 6 months prior to Day 1 * History of known primary immunodeficiency or is considered immunocompromised * Has been treated for a parasitic infection in the past 6 months * Participant has active HBV or HCV or is positive for HIV * Participant has active or latent TB * Stool positive for Clostridioides difficile toxin at Screening * Concomitant primary sclerosing cholangitis. * History of active major depressive episode or suicidal ideation * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients * Diagnosis of non-UC or confounding GI conditions including Crohn's disease, indeterminate colitis, microscopic colitis, ischemic or radiation colitis. * Disease limited to isolated ulcerative proctitis (\<15 cm). * Unresected colonic dysplasia or unresected adenomatous colonic polyps, fulminant colitis, toxic megacolon, bowel perforation, current colonic strictures, fistulae, stoma, ileostomy, colostomy, abdominal abscess, or anticipated need for colectomy during the study. * History of extensive colonic resection * History of drug or alcohol abuse * Laboratory values outside of the normal range considered clinically significant by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ulcerative colitis (UC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.